Prudential Financial’s SpringWorks Therapeutics SWTX Stock Holding History

Prudential Financial’s Portfolio SWTX Stock Details SWTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-8,895	Closed	-$418K	–	2524
2025 Q2	$418K	Buy	8,895 +3,645	+69%	+$162K	﹤0.01%	1995
2025 Q1	$232K	Buy	+5,250	New	+$242K	﹤0.01%	2032
2024 Q2	–	Sell	-4,894	Closed	-$241K	–	2787
2024 Q1	$241K	Buy	+4,894	New	+$226K	﹤0.01%	2414
2022 Q2	–	Sell	-9,930	Closed	-$560K	–	2742
2022 Q1	$560K	Buy	+9,930	New	+$568K	﹤0.01%	2152
2021 Q4	–	Sell	-53,610	Closed	-$3.4M	–	2696
2021 Q3	$3.4M	Buy	53,610 +24,385	+83%	+$1.88M	﹤0.01%	1190
2021 Q2	$2.41M	Buy	29,225 +18,390	+170%	+$1.4M	﹤0.01%	1389
2021 Q1	$797K	Buy	+10,835	New	+$849K	﹤0.01%	1950
2020 Q2	–	Sell	-18,166	Closed	-$491K	–	2463
2020 Q1	$491K	Sell	18,166 -100	-0.5%	-$3.26K	﹤0.01%	1917
2019 Q4	$703K	Buy	+18,266	New	+$427K	﹤0.01%	1969

Other funds holding SWTX

DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $20.6B AUM 34.61% 1-Year Est. Return

Prudential Financial's SWTX Position: Q3 2025 in Review

Prudential Financial sold out of SpringWorks Therapeutics (SWTX) in Q3 2025, closing a stake of 8,895 shares — an estimated $418K sold.

Prudential Financial first reported a position in SWTX in Q4 2019 and held it in 9 quarters. The position peaked at $3.4M in Q3 2021. 3 funds tracked by Wall St. Rank hold SWTX as of Q3 2025.

Prudential Financial reported no remaining SpringWorks Therapeutics position as of Q3 2025 after selling out during the quarter.
Prudential Financial sold 8,895 SpringWorks Therapeutics shares in Q3 2025, an estimated $418K.
Prudential Financial first reported a position in SpringWorks Therapeutics in Q4 2019 and held it in 9 quarters.
Prudential Financial's SpringWorks Therapeutics position peaked at $3.4M in Q3 2021.
3 funds tracked by Wall St. Rank held SpringWorks Therapeutics as of Q3 2025.

Based on Prudential Financial's 13F filing for Q3 2025, filed 13 Nov 2025.